
‘Time mirrors' are actually a real thing, experts say: ‘Like pressing undo on the universe'
Physicists in New York have pulled off what sounds like a page ripped from a sci-fi script: They've confirmed that 'time mirrors,' a trippy phenomenon where waves literally reverse in time — are real.
The mind-bending experiment, led by Dr. Hussein Moussa at the Advanced Science Research Center at CUNY, involved tinkering with a futuristic 'metamaterial' — a strip of metal embedded with electronic components.
Advertisement
3 The sci-fi-style breakthrough, led by Dr. Hussein Moussa at CUNY's Advanced Science Research Center, used a futuristic 'metamaterial' to bend the rules of time itself.
Tsyb Oleh – stock.adobe.com
When juiced with a precise burst of energy, the setup caused an electromagnetic wave to do the impossible: to flip the direction of time, as reported by Earth.com — or, as one TikTokker put it, 'Like pressing undo on the universe.'
'This is experimental physics catching up to what mystics, mushrooms and mad geniuses have been saying for decades,' said TikTok creator @psychonautics in a recent video.
Advertisement
'Time is not a line. It's a wave. And baby, we're just learning to surf it.'
The wave reversal doesn't just bounce a signal back in space like your average mirror — it scrambles the whole timeline. The wave's frequency shifts — and suddenly — it's like rewinding reality.
Scientists say this discovery, published in 'Nature Physics,' could one day revolutionize data transmission and computing. But for now, it's mostly blowing minds online.
Advertisement
More experiments will most likely follow this discovery.
And while physicists are bending time in the lab, neuroscientists say the human brain may already be doing it naturally.
3 Experts say the breakthrough could one day flip the script on data transmission and computing. For now? It's just melting brains across the internet.
New Africa – stock.adobe.com
Back in 2021, scientists from France and the Netherlands discovered that our brains possess 'an internal or inherent flow of time, that was not driven by something going on in the external world,' according to neuroscientist Leila Reddy, who sat down with Vice for an interview.
Advertisement
Her team studied epilepsy patients with electrodes implanted in their brains and found 'time cells' firing — even in the absence of external cues.
'These patients have severe, drug-resistant epilepsy and are awaiting surgery,' Reddy told Vice. 'Once the electrodes are inserted into the brain, we ask the patients if they are willing to participate in short experiments for us.'
The brain's inner clock, Reddy explained, could be the key to 'mental time travel' — the way we encode not just what happened, but when and where.
3 While those in labs are busy bending time with high-tech 'time mirrors,' neuroscientists say the human mind might already be pulling off a similar sci-fi stunt — no gadgets required.
mikhail_kayl – stock.adobe.com
'Time cells could provide the scaffolding for representing the 'when,'' she added.
In other words, while physicists are flipping waves, your neurons might be flipping through your past like a mental VHS tape.
Between time-bending materials and our own memory machinery, the past isn't as fixed as we thought — and the future just got a lot weirder.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hamilton Spectator
23-07-2025
- Hamilton Spectator
Aptean Launches GenAI Query in AppCentral
ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) — Aptean, a global provider of enterprise software, today announced the launch of GenAI Query, a mobile-first conversational intelligence feature within AppCentral, its AI-powered platform. Purpose-built to deliver real-time insights from complex business data, GenAI Query eliminates the need for dashboards, technical expertise, or delays. GenAI Query empowers frontline managers; operations leads and finance teams to ask natural-language questions like: 'Where are my fulfilment bottlenecks?' 'Which SKUs are eroding our margin?' They receive real-time answers, right when and where decisions are made. GenAI Query cuts through reporting delays and streamlines decision-making across every level of the organization. Modern manufacturing and distribution teams operate under relentless pressure to move fast — yet decision-making is often stalled by complex reports, fragmented systems and manual analysis. Buried in complex reports, fragmented systems and manual analysis, information remains out of reach. The result? A widening gap between data and decisive action. GenAI Query is the intelligence engine of AppCentral and a cornerstone of the Aptean Intelligence Suite. What sets it apart is Aptean's deep industry expertise and its ability to deliver tailored insights across discrete manufacturing, food and beverage, finance, transportation and apparel. With seamless integration and enterprise-grade security features – such as role-based access and audit trails - GenAI Query accelerates data-driven decision-making without compromising control. GenAI Query transforms enterprise decision-making by: AppCentral is the foundation for our customers to harness the power of AI - GenAI Query is the intelligence that brings it to life,' said TVN Reddy, CEO of Aptean. 'It's the difference between staring at a dashboard and having a direct, insightful conversation with your business. Customers don't just want data - they need clear answers that drive better outcomes. GenAI Query puts real-time enterprise intelligence at their fingertips.' 'GenAI Query makes business data instantly useful,' Reddy continued. 'Ask a simple question like 'What's my inventory risk this week?' and get contextual insight drawn straight from live systems. No coding. No delay. Just answers - delivered precisely when and where they're needed. With GenAI Query, every employee becomes an insight-driven decision-maker. The future of enterprise intelligence is immediate and conversational.' With thousands of customers now onboarded to AppCentral, Aptean is accelerating scalable AI adoption – giving customers the clarity, speed and control they need to make faster, smarter decisions. About Aptean: Aptean is a global provider of industry-specific software that helps manufacturers and distributors effectively run and grow their businesses. Aptean's solutions and services help businesses of all sizes to be Ready for What's Next, Now®. Aptean is headquartered in Alpharetta, Georgia and has offices in North America, Europe and Asia-Pacific. To learn more about Aptean and the markets we serve, visit . Logility is a Registered Trademark of Logility, Inc. Aptean and Ready for What's Next, Now are Registered Trademarks of Aptean, Inc. All other company and product names are trademarks of the respective companies with which they are associated. MEDIA INQUIRIES MediaRelations@ A PDF accompanying this announcement is available at A video accompanying this announcement is available at


Eater
11-07-2025
- Eater
Our Favorite Do-It-All Breville Countertop Oven Is $80 Off for Prime Day
is the commerce writer at Eater, and an award-winning writer with bylines in GQ, VICE, The Daily Beast, and other publications. A curious home cook with a deep love of Polish cabbage rolls, her devotion to food service journalism knows no bounds. Well, folks, the tornado of Amazon Prime Day deals is winding down, but — wait, what's that glimmering in the eye of the deals storm? Why, it's the Breville Smart Oven, aka Eater's favorite air-fryer-toaster–convection-oven combo appliance, for 20% percent off. I'd know the gentle shine of its brushed stainless steel design anywhere… The Breville Smart Oven is just one of those appliances that stays top-of-mind amongst the Eater shopping team; many of us are apartment-dwellers looking for multi-functional appliances that are worthy of our limited counter space. And when Eater contributor Charley Lanyon put five high-tech toaster ovens to the test, the Breville was a clear winner in terms of its ability to replace multiple other gadgets (and even your full-size oven). This beast is an air fryer, convection oven, toaster oven, and a dehydrator — basically a full-blown sous chef, to paraphrase Lanyon, who goes on to explain how the appliance's Element IQ system adjusts the power of its heating elements to cook food faster and more evenly. At nearly two feet in length, the Breville is big enough to take on an entire roast chicken, and considering that it could function as a 'real' oven for someone in a very small apartment, it's worthy of its girth. Is this the only toaster oven that could rock your world that's on sale for Prime Day? Hardly. Consider the stylish Japanese cult-fave toaster the Balmuda, which has a steam feature that's a godsend for reviving day-old pastries and stale bread. (It's 20% off right now, too.) If you love doughy toast that's crispy on the outside but so very soft on the inside, don't miss that deal, either. But it's Breville's model that took home the crown for its combination of functionality, aesthetics, and genuinely cool bells and whistles. And if you're tired of settling for 'meh' appliances that collect dust, the Breville may just be the best big little oven to blow your socks off (and perfectly crisp your chicken). The Breville Smart Oven Air Fryer Pro is on sale at Amazon. Check out more of Eater's Amazon Prime Day coverage here.


Associated Press
07-07-2025
- Associated Press
PathMaker Neurosystems Announces Publication of First Study Demonstrating Increased Survival in an ALS Mouse Model After Treatment With Non-Invasive Neuromodulation
Boston, MA and Providence, RI, July 07, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. ('PathMaker'), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for treating Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease), today announced the publication of groundbreaking research in Frontiers in Neurology demonstrating that its proprietary multi-site direct current stimulation (Multi-Site DCS) technology significantly extended survival time and reduced motor neuron degeneration in the widely used SOD1-G93A mouse model of ALS. This important study marks the first demonstration of any non-invasive neuromodulation technique delivering statistically significant survival benefits in an ALS mouse model. The results are compelling, with treated mice exhibiting a 74% increase in survival time from disease onset compared to untreated counterparts. The published paper, ' Multi-path direct current spinal stimulation extended survival in the SOD1-G93A model of amyotrophic lateral sclerosis,' has as senior author, Dr. Zaghloul Ahmed, Professor and Chairman, Department of Physical Therapy and Professor, Center for Developmental Neuroscience, CUNY and Scientific Founder of PathMaker Neurosystems. Beyond extending survival and mitigating motor neuron degeneration, this NIH-funded research highlights that Multi-Site DCS treatment also reduced spinal excitability, decelerated motor dysfunction progression, activated protein degradation pathways and lowered SOD1 protein levels in motor neurons. 'These results provide compelling evidence that our non-invasive treatment approach can meaningfully impact disease progression,' said Nader Yaghoubi, M.D., Ph.D., Co-Founder and Chief Executive Officer of PathMaker Neurosystems. 'The mechanistic insights from this paper underscore the potential of non-invasive Multi-Site DCS as a transformative disease-modifying intervention for ALS. Our ongoing efforts are directed towards translating this innovative treatment into clinical development, with the CALM trial, Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability, our second ALS clinical trial, now in progress ( NCT06649955 ). This trial, funded by the U.S. Department of Defense ALSRP program, represents a significant advancement in our journey to bring this novel modality to clinical use. About PathMaker Neurosystems Inc. PathMaker Neurosystems is a clinical-stage neuromodulation company developing a breakthrough non-invasive approach to the treatment of amyotrophic lateral sclerosis (ALS). More than 34,000 people in the U.S. and 350,000 people worldwide are estimated to suffer from ALS. PathMaker is collaborating with world-class institutions to develop and bring to market first-in-class products for treating ALS and other neurological disorders with very high unmet medical need. The MyoRegulator® platform is based on PathMaker's proprietary technology for multi-site direct current stimulation (Multi-Site DCS). MyoRegulator® has been previously designated by the US Food and Drug Administration (FDA) as a 'FDA Breakthrough Device.' MyoRegulator® and MyoRegulator® ALS are investigational medical devices and are limited by Federal law to investigational use only. For more information, please visit the company website at Source: PathMaker Neurosystems Inc. Media contact: PathMaker PR (617) 535-7696 [email protected]